 Hi, my name is David Siegel, I'm the Chief of the Miloma Division here at the John Thur Cancer Center. I'm also the founding director of the Institute for Multimiloma at the Center for Discovery and Innovation at the Medical School Campus. I've worked at a number of institutions, including some of the best known in the world. The differences between John Thur and other places that I've worked and other places that I know is that we're a community oncology program even though we're a huge oncology program and a major referral program and I think that's the biggest difference about my experiences here and I've been here 19 years now. My team is the one that's taking care of them and so it's a much more personal relationship than I think exists at other cancer centers. We have invested an extraordinary amount of infrastructure to developing expertise and capabilities in treating people with Miloma, diagnosing people with Miloma and we've been participants in developing basically all of the therapies that have become important in multiple Miloma. We have literally the best radiologists in the world, the nephrologists who have gone out of their way to learn what is important about Miloma, cardiologists who have been taking care of Miloma for decades now. We have nurses who all they do is take care of Miloma. Infusion nurses who all they do is actually give the drugs to Miloma patients all day and understand the potential consequences or know what their patient's veins look like and then we have non-professional staff, our MAs and our schedulers and the people who sit at the reception desk know every single patient's name, know everything that's important to know. It's important to have a family that works together.